Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
7,240 total articles
Applied Optoelectronics (AAOI) has become a go-to supplier for optical transceivers and laser diodes as hyperscalers and AI data-center builders accelerate connectivity spending. The stock has already rallied dramatically, but balance-sheet strength, tight short interest and clear demand catalysts make a tactical long attractive from current levels…
AppLovin (APP) is trading like a growth software name with monster profitability. Strong Q1 prints and the roll-out of Axon AI have pushed revenue and margins higher; the market is pricing a premium (P/E ~42, P/S ~27). This trade idea outlines a disciplined long with entry at $497.00, stop at $430.00 and a $650.00 target over a 180 trading-day hori…
Electromed (ELMD) is a compact medical-specialties company punching above its weight: roughly $72M of implied revenue, double-digit free cash flow margins, zero debt and solid returns on capital. Technicals are constructive and the stock trades below a recent $40 52-week high. We outline a long trade with a $37.00 entry, $33.00 stop and $45.00 targ…
RH (Restoration Hardware) is a high-end furniture and home-lifestyle name trading well below prior highs despite solid free cash flow, expanding international presence, and continued pricing power. At roughly $153, shares offer asymmetric upside to $220 over a multi-month horizon while offering an attractive free cash flow yield; downside is real, …
Micron sits at the center of an AI-driven memory squeeze. At roughly $990 today, the stock is expensive by some multiples, but the company's cash generation, low leverage and the prospect of sustained DRAM/NAND pricing make a long position attractive. This trade plan lays out exact entry, stop and target levels across a 180-trading-day horizon and …
Nabors is showing signs of an earnings inflection backed by improving rig demand and operational wins. The stock is cheap on P/E and EV/EBITDA while technicals show constructive momentum. This trade idea lays out a mid-term (45 trading days) long with entry, target, and stop-loss, plus catalysts and risks that would change the view.
Protagonist (PTGX) is trading like a pure clinical biotech despite meaningful de-risking: a partner-approved oral IL-23R pill (Icotyde) that just delivered a $50M milestone and an NDA for rusfertide in polycythemia vera moving toward potential approval. The shares have momentum, a $7.06B market cap and limited debt, creating a tradeable long with d…
Broadcom's guidance note that gross profit margins will continue to fall is a clear structural headwind for a stock trading at premium multiples. Fundamentals still look strong, but the market is paying a very high price for near-term margin stability. This trade idea proposes a short-swing (45 trading days) position sized to the risk, with explici…
Nano Labs (NA) is a small, China-based fabless semiconductor firm with high-performance computing chips, smart NICs and distributed storage products. The stock trades at a $41M market cap, P/E ~1.85 and P/B ~0.38, while recent partnerships and product rollouts give the company optionality into North American AI data centers. This is a high-risk, ta…
Zhihu trades at a sub-$300M market cap with a price-to-book under 0.5 and signs of recent operational improvement. Elevated short interest and AI-driven threats make this a volatile trade, but the combination of non-GAAP profitability quarters, margin expansion commentary, and board refreshes argue for a tactical long with tight risk controls.
Sea (SE) has a Shopee profitability problem that is visible in short-term margin squeezes. But the company’s balance sheet, record adjusted EBITDA, and accelerated revenue growth give multiple levers to restore profitability and drive re-rating. This trade idea lays out specific entry, stop, and target levels tied to a 180 trading-day thesis.
G Mining Ventures is being priced like a steady-state miner despite being in the mine-builder phase. If management hits near-term permitting and financing milestones, the stock should re-rate. This trade targets a meaningful upside while protecting capital if the developer stalls.
Range Resources (RRC) looks attractively priced at $38.58 with last reported free cash flow near $878M and a low debt load. Strong realized energy prices and recent dividend increases support a thesis that Range can generate roughly $800M of free cash flow in 2026, underpinning earnings, buybacks and a higher dividend. The trade: enter $38.58, targ…
Capital One has retraced roughly 27% from its January highs, trading near $185 and offering an attractive risk-reward for a tactical long. The Discover acquisition and targeted $2.7B of synergies, improving auto loan performance, strong free cash flow, and a modest balance sheet give the company room to reclaim lost ground. I recommend a mid-term s…
Progressive has engineered industry-leading premium growth and underwriting results. With a market cap near $119B, a P/E around 10x and strong free cash flow, the stock looks actionable on a mid-term rebound. Expect underwriting margins to normalize from cyclical highs, but continued share gains, telematics advantages, and investment income should …
Revolution Medicines delivered a landmark Phase 3 RASolute 302 result for daraxonrasib that doubled median overall survival in previously treated metastatic pancreatic cancer and produced a 60% reduction in risk of death. That clinical leap turns a clinical-stage oncology name into a commercial opportunity. We upgrade our stance to a tactical long …
Ares Management (ARES) has been punished alongside private-credit peers on liquidity fears. The company’s diversified fee streams, solid free cash flow of $1.59B, and a current dividend that pays out roughly $5.40 annually per share argue the pullback overstates structural risk. We outline a mid-term trade: buy into weakness with a $135 entry, a $1…
Prime Medicine has moved from promise to early clinical proof with prime editing data and a NEJM publication for PM359. At a market cap near $500M and a cash runway into 2027, the stock offers an asymmetric payoff if additional programs validate. This trade idea outlines a long entry with strict risk controls and key catalysts to watch.
WhiteFiber is uniquely positioned in the AI infrastructure market after securing multi-year colocation capacity deals. With a market cap near $950M, constrained float and rising utilization, the stock has asymmetric upside into prior highs if execution continues. This trade targets a move toward $36 in the next 45 trading days with a disciplined st…
CMB.TECH has strengthened its fleet and is benefiting from elevated freight rates tied to shipping disruptions, but the stock trades well above last summer's lows and already reflects a meaningful recovery. We prefer a measured, swing-oriented long with clearly defined risk controls: enter at $15.50, target $17.50 and stop $13.80 for a mid-term tra…
SouthState Bank Corporation has shown consistent profitability, low leverage and tangible scale gains from recent M&A. With a P/E near 10.5, a 2.4% dividend yield and an improving technical setup, SSB warrants an upgrade to a constructive stance. This trade idea lays out an entry, stop and target for a long-term (180 trading days) position while hi…
Workday's accelerating AI adoption (agentic AI up ~200% y/y and nearing $500M ARR) paired with a free cash flow yield north of 9% creates a workable trade: buy into the AI-driven re-acceleration at modest FCF multiples, with a tight stop and a 30%+ upside target over the next 45 trading days.
AppLovin's recent beats and accelerating conversion rates are translating into both revenue growth and outsized margins. At a market cap near $167B and a P/E around 42x, the stock already prices optimism, but the combination of product-led ad performance gains, AI-enabled targeting, and manageable short interest sets up a disciplined long trade wit…
Millicom (TIGO) combines a rare growth path for a telecom with a 3%+ dividend yield. Recent acquisitions and improving equity free cash flow create room for multiple expansion while the balance sheet target (2.5x leverage) keeps risk contained. Trade plan provided for a mid-term (45 trading days) position.
Nanobiotix (NANO) is a specialty biotech with a physics-based radioenhancer platform and an underappreciated royalty engine. The setup today favors a directional long: modest entry risk for substantial upside if near-term clinical/regulatory catalysts and royalty monetization materialize. Trade plan below targets a 45-trading-day horizon with clear…
